University of Minnesota
Office for Technology Commercialization

Office for Technology Commercialization homeOTC

For Industry

University Licensing Policies

We adhere to both University and federal policies while we manage the intellectual property assets of the University. We have many experienced staff members able to work with you to determine the best possible licensing terms to give you the greatest chance of commercial success. For additional information on the policies that guide us, please review the following links:

University Regents Commercialization of Intellectual Property Policy

This policy governs patents and the ownership, commercialization, and dissemination of intellectual property rights in technology created at the University.

University Regents Conflict of Interest Policy

This policy governs individual conflict of interest and applies to covered individuals at the University.

University Regents Administrative Policy on Conflict of Interest

This administrative policy is concerned with implementing the Individual Business or Financial Conflict of Interest Board of Regents Policy.

Office for Institutional Compliance

The Office for Institutional Compliance provides independent oversight over the University of Minnesota’s compliance programs. The Director, who reports to the President, is responsible for coordinating and monitoring these programs to assure that the University is compliant with federal, state and local laws, and regulations as well as University policies.

Bayh-Dole Act

Enacted on December 12, 1980, the Bayh-Dole Act (P.L. 96-517, Patent and Trademark Act Amendments of 1980) created a uniform patent policy among the many federal agencies that fund research, enabling small businesses and non-profit organizations, including universities, to retain title to inventions made under federally-funded research programs

Research Highlight

Robert Vince


Abacavir, the antiretroviral drug sold under the brand name Ziagen® by GlaxoSmithKline, was invented by researchers at the University of Minnesota with financial support from the federal government.

The anti-HIV medication is in a category of HIV medications called nucleoside reverse transcriptase inhibitors, or NRTIs. Ziagen prevents HIV from altering the genetic material of healthy T-cell, which prevents the cells from producing new virus and decreases the amount of virus in the body.

Ziagen, which received approval from the U.S. Food and Drug Administration in 1998, is always combined with at least two other anti-HIV drugs, or in combination tablets.


Story from the AUTM Better World Report